AI
AIMT

ArchPoint Investors’s Aimmune Therapeutics AIMT Stock Holding History

ArchPoint Investors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-112,099
Closed -$2.5M – 141
2019
Q1 		$2.5M Buy
+112,099
New +$2.64M 0.75% 26

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ArchPoint Investors's AIMT Position: Q2 2019 in Review

ArchPoint Investors sold out of Aimmune Therapeutics (AIMT) in Q2 2019, closing a stake of 112,099 shares — an estimated $2.5M sold.

ArchPoint Investors first reported a position in AIMT in Q1 2019 and held it in 1 quarter. The position peaked at $2.5M in Q1 2019. 125 funds tracked by Wall St. Rank hold AIMT as of Q2 2019.

  • ArchPoint Investors reported no remaining Aimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
  • ArchPoint Investors sold 112,099 Aimmune Therapeutics shares in Q2 2019, an estimated $2.5M.
  • ArchPoint Investors first reported a position in Aimmune Therapeutics in Q1 2019 and held it in 1 quarter.
  • ArchPoint Investors's Aimmune Therapeutics position peaked at $2.5M in Q1 2019.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2019.

Based on ArchPoint Investors's 13F filing for Q2 2019, filed 26 Jul 2019.